Trials / Terminated
TerminatedNCT00210366
Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG) · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the trial is to assess the therapeutic activity of idarubicin as salvage treatment in patients with recurrent or progressive lymphoma in the central nervous system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Idarubicin |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2010-07-01
- First posted
- 2005-09-21
- Last updated
- 2010-07-30
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT00210366. Inclusion in this directory is not an endorsement.